

FEB 22 2002

K02016
p1/2³⁶

510(k) SUMMARY

The 510(k) Summary is submitted in accordance with 21 CFR Part 807, Section 807.92

Submitter's Name: Guidant Corporation
Endovascular Solutions

Submitter's Address: 3200 Lakeside Drive
Santa Clara, CA 95052

Telephone: (408) 845-1419
Fax: (408) 845-3743

Contact Person: Curtis Truesdale

Date Prepared: January 16, 2002

Device Trade Name: AGILTRAC™ .018 Peripheral Dilatation Catheter

Device Common Name: Percutaneous Transluminal Angioplasty Catheter

Device Classification Name: LIT

Device Classification: Class II

Summary of Substantial Equivalence:

The AGILTRAC™ .018 Peripheral Dilatation Catheter consisting of balloon diameters of 4.0-10.0 mm and 12.0 mm, balloon lengths of 20, 30, 40 and 60 mm with a system lengths of 80 cm and 135 cm is substantially equivalent to Guidant's OTW VIATRAC™ 18 Peripheral Dilatation Catheter consisting of balloon diameters of 6.0-10.0, balloon lengths of 20, 30, and 40 mm with system lengths of 75cm and 135 cm. The AGILTRAC™ .018 Peripheral Dilatation Catheter is substantially equivalent to the legally marketed comparison device with respect to design, materials, method of delivery and intended use.

Device Description:

The AGILTRAC™ .018 Peripheral Dilatation Catheter is a two-lumen catheter with a balloon near the distal tip. One lumen is used for inflation of the balloon with contrast medium; the other lumen permits the use of a guide wire to facilitate advancement of the catheter to and through the stenosis to be dilated, and the injection of contrast and/or medication through the distal tip.

The balloon has radiopaque marker(s) to aid in positioning the balloon in the stenosis, and is designed to provide an expandable segment of known diameter and length at a specific pressure.

Indications for Use:

The AGILTRAC™ .018 Peripheral Dilatation Catheter is intended:

- To dilate stenoses in the peripheral arteries (iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal arteries); and
- For the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

Technological Characteristics:

Comparisons of the subject and predicate device show that technological characteristics such as materials, biocompatibility, mode of operation, performance properties, sterilization and packaging are substantially equivalent to the currently marketed predicate device, the OTW VIATRAC™ 18 Peripheral Dilatation Catheter.

Performance Data:

The safety and effectiveness of the AGILTRAC™ .018 Peripheral Dilatation Catheter has been demonstrated through data collected from *in vitro* bench tests and analyses.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

FEB 22 2002

Mr. Curtis D. Truesdale
Regulatory Affairs Associate
Guidant Corporation
3200 Lakeside Drive
Santa Clara, CA 95054-2807

Re: K020161
Trade Name: AGILTRAC™ .018 Peripheral Dilatation Catheter
Regulation Number: 21 CFR 870.1250
Regulation Name: Percutaneous catheter.
Regulatory Class: II (two)
Product Code: DQY
Dated: February 14, 2002
Received: February 15, 2002

Dear Mr. Truesdale:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality


Page 2 - Mr. Curtis D. Truesdale

systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman", is written over the typed name.

Bram D. Zuckerman, M.D.
Acting Director
Division of Cardiovascular
and Respiratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): K020161

Device Name: AGILTRAC™ .018 Peripheral Dilatation Catheter

Indications for Use:

The AGILTRAC™ .018 Peripheral Dilatation Catheter is indicated for dilatation of stenoses in the peripheral arteries (iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal arteries) and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

[Signature]
Division of Cardiovascular & Respiratory Devices
510(k) Number K020161